Crohn’s Disease Therapeutics Market size was valued at US$ 6.67 Bn in 2021 and the total revenue is expected to grow at 5.9 % through 2022 to 2029, reaching nearly US$ 10.55 Bn.Crohn’s Disease Therapeutics Market Overview:
Inflammatory bowel disease (IBD) is a form of the disease that affects the intestines (IBD). It causes stomach pain, severe diarrhea, exhaustion, weight loss, and starvation by inflaming your digestive tract. Crohn's disease causes inflammation in various parts of the digestive tract, depending on the individual. This inflammation frequently progresses to the bowel's deeper layers.To know about the Research Methodology :- Request Free Sample Report
Crohn’s Disease Therapeutics Market Dynamics:
The rising frequency of the disease, combined with a growth in the number of pipeline medications, is likely to drive the market. Industrialization, environmental variables such as variances in sun exposure, changes in nutrition, smoking, and hereditary traits have all contributed to a rise in Crohn's disease prevalence in developing countries. Irritable bowel illness affects about 1.8 million Americans each year, according to the Centers for Disease Control and Prevention (CDC). The industry's growth is being guided by constant efforts in the development of biosimilars. One of the key advantages of biosimilars is their low cost, which has resulted in significant savings in the healthcare systems of the US. and Europe. Moreover, Increased availability of biological medicines, as a result of lower costs, can improve patient care. In the future, the sector is expected to be driven by the development of innovative biological agents and anti-cytokine agents with different mechanisms of action, as well as the use of stem cells in disease treatment. TNF agents like Infliximab and Adalimumab, for example, have shown to be effective in treating the condition. Partnerships with research institutes and the purchase of minor firms are two significant techniques used by players to achieve a stable market position. The development of novel therapy products is also a priority to boost the market expansion. For example, Johnson & Johnson one of the leading healthcare industry proclaimed in 2016 that the FDA has approved Stelara for the treatment of Crohn's disease.Crohn’s Disease Therapeutics Market Segment Analysis:
The Non-Surgical segment is anticipated to adhere to the growth of the Crohn’s Disease Therapeutics Market. The non-surgical sub-segment is dominating the growth of the therapeutic segment in the forecast period with a market share of 49% in 2021. The non-surgical segment is further divided into subcategories such as anti-Inflammatory, Immune system suppressors, Antibiotics, Others. The anti-inflammatory segment conquered the Crohn’s disease therapeutics market with the highest market share in 2021. Anti-inflammatories are the first line of drugs treatment and are targeted effectively. During the projected period, the immune system suppressors segment is also expected to grow at a CAGR of 3.2%. Immune suppressors have been demonstrated to be both safe and effective. The segment is predicted to be driven by lower rates of mortality, hospitalization, and surgery, as well as enhanced patient quality of life. Immune system suppressors are now being developed by companies like Genentech Inc. and Celgene Corporation to treat this problem. The immune system suppressor etrolizumab, developed by Genentech Inc., is now being explored in clinical studies. This medicine showed promise in phase II clinical studies in terms of safety and efficacy. The certification of these items could aid the future growth of this business.Crohn’s Disease Therapeutics Market Regional Segment:
In terms of revenue, North America dominated the global market in 2021. The rise of the disease is fuelled by established R&D infrastructure, the development of novel medicines, and the increased prevalence of the condition. The Crohn's and Colitis Foundation estimates that 1.6 million Americans have the disease. Further, Due to the obvious high frequency of the disease and the strong healthcare infrastructure in place, new treatment options are being developed and made available to patients. In addition, A high prevalence of Crohn's disease in the region, particularly in Canada and the US. unhealthy lifestyles such as fast food consumption and smoking habits, progressive healthcare infrastructure, and innovative healthcare solutions are all factors contributing to the growth of the market. The objective of the report is to present a comprehensive analysis of the Crohn’s Disease Therapeutics Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the Crohn’s Disease Therapeutics Market dynamics, structure by analyzing the market segments and project the Crohn’s Disease Therapeutics Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Crohn’s Disease Therapeutics Market make the report investor’s guide.Crohn’s Disease Therapeutics Market Scope: Inquire before buying
Crohn’s Disease Therapeutics Market Report Coverage Details Base Year: 2021 Forecast Period: 2022-2029 Historical Data: 2017 to 2021 Market Size in 2021: US $ 6.67 Bn. Forecast Period 2022 to 2029 CAGR: 5.9% Market Size in 2029: US $ 10.55 Bn. Segments Covered: by Therapeutic Type • Surgical • Non-Surgical o Anti-Inflammatory o Immune system suppressors o Antibiotics o Others
Crohn’s Disease Therapeutics Market, by Region
• North America • Europe • Asia Pacific • The Middle East and Africa • South AmericaCrohn’s Disease Therapeutics Market Key Players
• AbbVie Inc. • Allergan, Inc. • Bayer AG • Bristol-Myers Squibb • Boehringer Ingelheim GmbH • F. Hoffmann-La Roche • Eli Lilly and Co. • GlaxoSmithKline plc • Janssen Biotech, Inc. • Johnson & Johnson • Novartis International AG • Pfizer Inc. • Sanofi • Takeda Pharmaceutical Company Limited • Salix Pharmaceuticals • Gilead Sciences Inc. • Genentech Inc. • UCB India Private Limited.FAQs:
1. What is the Crohn’s Disease Therapeutics Market value in 2021? Ans: The Crohn’s Disease Therapeutics Market value in 2021 was estimated as 6.67 Billion USD. 2. What is the Crohn’s Disease Therapeutics Market growth? Ans: The Crohn’s Disease Therapeutics Market is anticipated to grow with a CAGR of 5.9% in the forecast period and is likely to reach USD 10.55 Billion by the end of 2029. 3. Which Therapeutic Type segment is expected to dominate the Crohn’s Disease Therapeutics Market during the forecast period? Ans: Non-Surgical segment accounted for the largest share 49% in 2021. This is attributed to the adoption higher medications and technological investment in medical devices which are less invasive. 4. Which region is expected to dominate the Crohn’s Disease Therapeutics Market during the forecast period? Ans: North America dominated the global market in terms of revenue in 2021. Established R&D infrastructure, development of novel therapeutics, and rising prevalence of the disease are key factors contributing to its growth. 5. What is the key driving factor for the growth of the Crohn’s Disease Therapeutics Market? Ans: Key factors that are driving the Crohn’s Disease Therapeutics market growth include the Growing prevalence of the disease, along with increase in number of pipeline drugs, is expected to be a key factor driving the market.
1.Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Technology 2.3.2. Primary Research 2.3.2.1. Data from Primary Technology 2.3.2.2. Breakdown of Primary Technology 3. Executive Summary: Crohn’s Disease Therapeutics Market Size, by Market Value (US$ Mn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2021 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Crohn’s Disease Therapeutics Market 3.4. Geographical Snapshot of the Crohn’s Disease Therapeutics Market, By Manufacturer share 4. Crohn’s Disease Therapeutics Market Overview, 2021-2029 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porter Five Forces Analysis 4.1.6.1. Threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. Threat of Substitute Grades 4.1.6.5. Intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Crohn’s Disease Therapeutics Market 5. Supply Side and Demand Side Indicators 6. Crohn’s Disease Therapeutics Market Analysis and Forecast, 2021-2029 6.1. Crohn’s Disease Therapeutics Market Size & Y-o-Y Growth Analysis. 7. Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 7.1. Market Size (Value) Estimates & Forecast By Therapeutic Type, 2021-2029 7.1.1. Non-Surgical 7.1.1.1. Anti-Inflammatory 7.1.1.2. Immune system suppressors 7.1.1.3. Antibiotics 7.1.1.4. Others 7.1.2. Surgical 8. Crohn’s Disease Therapeutics Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast By Region, 2021-2029 8.1.1. North America 8.1.2. Europe 8.1.3. Asia-Pacific 8.1.4. Middle East & Africa 8.1.5. South America 9. North America Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 9.1. Market Size (Value) Estimates & Forecast By Therapeutic Type, 2021-2029 9.1.1. Non-Surgical 9.1.1.1. Anti-Inflammatory 9.1.1.2. Immune system suppressors 9.1.1.3. Antibiotics 9.1.1.4. Others 9.1.2. Surgical 10. North America Crohn’s Disease Therapeutics Market Analysis and Forecasts, By Country 10.1. Market Size (Value) Estimates & Forecast By Country, 2021-2029 10.1.1. US 10.1.2. Canada 10.1.3. Mexico 11. U.S. Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 11.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 12. Canada Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 12.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 13. Mexico Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 13.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 14. Europe Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 14.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 15. Europe Crohn’s Disease Therapeutics Market Analysis and Forecasts, By Country 15.1. Market Size (Value) Estimates & Forecast By Country, 2021-2029 15.1.1. U.K 15.1.2. France 15.1.3. Germany 15.1.4. Italy 15.1.5. Spain 15.1.6. Sweden 15.1.7. CIS Countries 15.1.8. Rest of Europe 16. U.K Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 16.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 17. France Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 17.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 18. Germany Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 18.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 19. Italy Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 19.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 20. Spain Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 20.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 21. Sweden Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 21.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 22. CIS Countries Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 22.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 23. Rest of Europe Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 23.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 24. Asia Pacific Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 24.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 25. Asia Pacific Crohn’s Disease Therapeutics Market Analysis and Forecasts, by Country 25.1. Market Size (Value) Estimates & Forecast By Country, 2021-2029 25.1.1. China 25.1.2. India 25.1.3. Japan 25.1.4. South Korea 25.1.5. Australia 25.1.6. ASEAN 25.1.7. Rest of Asia Pacific 26. China Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 26.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 27. India Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 27.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 28. Japan Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 28.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 29. South Korea Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 29.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 30. Australia Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 30.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 31. ASEAN Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 31.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 32. Rest of Asia Pacific Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 32.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 33. Middle East Africa Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 33.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 34. Middle East Africa Crohn’s Disease Therapeutics Market Analysis and Forecasts, by Country 34.1. Market Size (Value) Estimates & Forecast by Country, 2021-2029 34.1.1. South Africa 34.1.2. GCC Countries 34.1.3. Egypt 34.1.4. Nigeria 34.1.5. Rest of ME&A 35. South Africa Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 35.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 36. GCC Countries Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 36.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 37. Egypt Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 37.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 38. Nigeria Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 38.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 39. Rest of ME&A Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 39.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 40. South America Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 40.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 41. South America Crohn’s Disease Therapeutics Market Analysis and Forecasts, by Country 41.1. Market Size (Value) Estimates & Forecast by Country, 2021-2029 41.1.1. Brazil 41.1.2. Argentina 41.1.3. Rest of South America 42. Brazil Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 42.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 43. Argentina Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 43.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 44. Rest of South America Crohn’s Disease Therapeutics Market Analysis and Forecasts, 2021-2029 44.1. Market Size (Value) Estimates & Forecast By Therapeutic Type’s, 2021-2029 45. Competitive Landscape 45.1. Geographic Footprint of Major Players in the Crohn’s Disease Therapeutics Market 45.2. Competition Matrix 45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Fiber Grades, and R&D Investment 45.2.2. New Grade Launches and Grade Enhancements 45.2.3. Market Consolidation 45.2.3.1. M&A by Regions, Investment, and Verticals 45.2.3.2. M&A, Forward Integration and Backward Integration 45.2.3.3. Partnership, Joint Ventures, and Strategic Alliances/ Sales Agreements 45.3. Company Profile: Key Players 45.3.1. Pfizer 45.3.1.1. Company Overview 45.3.1.2. Financial Overview 45.3.1.3. Geographic Footprint 45.3.1.4. Grade Portfolio 45.3.1.5. Business Strategy 45.3.1.6. Recent Developments 45.3.2. AbbVie Inc. 45.3.3. Allergan, Inc. 45.3.4. Bayer AG 45.3.5. Bristol-Myers Squibb 45.3.6. Boehringer Ingelheim GmbH 45.3.7. F. Hoffmann-La Roche 45.3.8. Eli Lilly and Co. 45.3.9. GlaxoSmithKline plc 45.3.10. Janssen Biotech, Inc. 45.3.11. Johnson & Johnson 45.3.12. Novartis International AG 45.3.13. Sanofi 45.3.14. Takeda Pharmaceutical Company Limited 45.3.15. Salix Pharmaceuticals 45.3.16. Gilead Sciences Inc. 45.3.17. Genentech Inc. 45.3.18. UCB India Private Limited 46.Primary Key Insights